EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Adeno-associated virus-vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease

Shelly L Vaden iD, Allison R Kendall iD, Jonathan D Foster iD, Heidi L New, Jane S Eagleson, Jacky L May, Anne M Traas, Matthew J Wilson, Beth H McIntyre, Christian J Hinderer, Lauren K Olenick, James M Wilson

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16900 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2023. Verfasst von Shelly L Vaden und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, 27607, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Anemia, Erythropoietin, Hypertension. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A treatment of chronic kidney disease (CKD)-associated anemia in cats is needed. SB-001 is an adeno-associated virus-vectored (AAV)-based gene therapeutic agent that is administered intramuscularly, causing the expression of feline erythropoietin. Hypothesis/Objective We hypothesized that SB-001 injection would lead to a sustained increase in PCV in cats with CKD-associated anemia. Animals Twenty-three cats with International Renal Interest Society (IRIS) Stage 2 to 4 CKD-associated anemia were enrolled at 4 veterinary clinics.

Methods

In a prospective clinical trial, cats were treated with 1 of 3 regimens of SB-001 (Lo 1.2 × 109 genome copies [GCs] on Day 0; Lo ± Hi [supplemental 2nd dose of 3.65 × 109 GC on Day 42]; Hi 3.65 × 109 GC IM on Day 0) and followed for 70 days.

Results

A response to SB-001 at any time between Day 28 and Day 70 was seen in 86% (95% confidence interval 65, 97%) of all cats. There was a significant (P < .003) increase in PCV from Day 0 to Day 28 (mean increase 6 ± 6 percentage points [pp]; n = 21), Day 42 (8 ± 9 pp; n = 21), Day 56 (10 ± 11 pp; n = 17), and Day 70 (13 ± 14 pp, n = 14). Twelve cats were hypertensive at baseline, 4 of which developed encephalopathy during the study. An additional 6 cats became hypertensive during the study. Conclusions and Clinical Importance Results of this study suggest that SB-001 therapy represents a suitable single injection treatment that can address nonregenerative anemia in cats with CKD. It was generally well tolerated; however, hypertension and encephalopathy developed in some cats as previously described in association with erythropoiesis-stimulating agent therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicAnemiaErythropoietinHypertensionBrain DiseasesCat DiseasesCatsAnimalsDependovirusProspective StudiesGenetic Therapy

Stichwörter der Autor:innen

AAVcatsred blood cellsrenal disease

Substanzen

Erythropoietin

Autor:innen und Institutionen

  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, 27607, USA.
  • Friendship Hospital for Animals, Washington, DC, 20016, USA.
  • VCA Sacramento Veterinary Referral Center, Sacramento, California, 95287, USA.
  • Bleecker Street Consulting, New York, New York 10012, USA.
  • Scout Bio, Inc., Philadelphia, Pennsylvania, 19104, USA.
  • Beth Oman Clinical Consulting LLC, Kalamazoo, Michigan, 49004, USA.

ORCID-Profile: Shelly L Vaden, Allison R Kendall, Jonathan D Foster

Zitieren

APA

Vaden, S. L., Kendall, A. R., Foster, J. D., New, H. L., Eagleson, J. S., May, J. L., Traas, A. M., Wilson, M. J., McIntyre, B. H., Hinderer, C. J., Olenick, L. K., & Wilson, J. M. (2023). Adeno-associated virus-vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16900

Vancouver

Vaden SL, Kendall AR, Foster JD, New HL, Eagleson JS, May JL, et al. Adeno-associated virus-vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16900

BibTeX
@article{Vaden2023,
  author = {Vaden, Shelly L and Kendall, Allison R and Foster, Jonathan D and New, Heidi L and Eagleson, Jane S and May, Jacky L and Traas, Anne M and Wilson, Matthew J and McIntyre, Beth H and Hinderer, Christian J and Olenick, Lauren K and Wilson, James M},
  title = {Adeno-associated virus-vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16900}
}
Kostenlos starten →